Halsey Associates Inc. CT Acquires 12,370 Shares of Edwards Lifesciences Corp (EW)
Halsey Associates Inc. CT lifted its holdings in Edwards Lifesciences Corp (NYSE:EW) by 263.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 17,061 shares of the medical research company’s stock after acquiring an additional 12,370 shares during the period. Halsey Associates Inc. CT’s holdings in Edwards Lifesciences were worth $2,970,000 as of its most recent SEC filing.
Several other institutional investors have also added to or reduced their stakes in the company. Advisors Asset Management Inc. increased its position in shares of Edwards Lifesciences by 4.6% in the third quarter. Advisors Asset Management Inc. now owns 29,167 shares of the medical research company’s stock worth $5,078,000 after acquiring an additional 1,287 shares in the last quarter. HealthCor Management L.P. acquired a new stake in shares of Edwards Lifesciences in the third quarter worth $78,992,000. Summit Global Investments increased its position in shares of Edwards Lifesciences by 7.4% in the third quarter. Summit Global Investments now owns 21,570 shares of the medical research company’s stock worth $3,755,000 after acquiring an additional 1,490 shares in the last quarter. Point72 Asset Management L.P. acquired a new stake in shares of Edwards Lifesciences in the third quarter worth $801,000. Finally, TLP Group LLC increased its position in shares of Edwards Lifesciences by 163.6% in the third quarter. TLP Group LLC now owns 680 shares of the medical research company’s stock worth $118,000 after acquiring an additional 422 shares in the last quarter. 82.50% of the stock is owned by institutional investors.
In other Edwards Lifesciences news, Director Schack Wesley W. Von sold 1,319 shares of the stock in a transaction on Thursday, November 29th. The shares were sold at an average price of $160.96, for a total transaction of $212,306.24. Following the transaction, the director now directly owns 2,134 shares in the company, valued at approximately $343,488.64. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Donald E. Bobo, Jr. sold 5,500 shares of the stock in a transaction on Wednesday, October 10th. The shares were sold at an average price of $147.50, for a total transaction of $811,250.00. Following the transaction, the vice president now owns 25,490 shares in the company, valued at $3,759,775. The disclosure for this sale can be found here. Insiders have sold a total of 142,456 shares of company stock worth $21,146,590 over the last quarter. 1.84% of the stock is currently owned by insiders.
Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Tuesday, October 23rd. The medical research company reported $1.07 EPS for the quarter, beating the Zacks’ consensus estimate of $1.02 by $0.05. Edwards Lifesciences had a net margin of 20.67% and a return on equity of 30.11%. The firm had revenue of $906.60 million for the quarter, compared to the consensus estimate of $927.56 million. During the same period in the prior year, the firm posted $0.84 EPS. The firm’s revenue was up 10.4% compared to the same quarter last year. On average, research analysts expect that Edwards Lifesciences Corp will post 4.7 EPS for the current fiscal year.
Several research analysts have recently weighed in on the stock. SunTrust Banks upped their target price on shares of Edwards Lifesciences to $200.00 and gave the company a “buy” rating in a research note on Friday, September 28th. Bank of America downgraded shares of Edwards Lifesciences from a “buy” rating to a “neutral” rating in a research note on Tuesday, October 2nd. Guggenheim downgraded shares of Edwards Lifesciences from a “buy” rating to a “neutral” rating in a research note on Tuesday, October 2nd. Zacks Investment Research upgraded shares of Edwards Lifesciences from a “hold” rating to a “buy” rating and set a $185.00 target price for the company in a research note on Wednesday, September 26th. Finally, Morgan Stanley upped their target price on shares of Edwards Lifesciences from $157.00 to $180.00 and gave the company an “overweight” rating in a research note on Friday, December 7th. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and thirteen have issued a buy rating to the company’s stock. Edwards Lifesciences currently has an average rating of “Buy” and a consensus target price of $162.85.
TRADEMARK VIOLATION WARNING: This piece was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece on another website, it was stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.thecerbatgem.com/2018/12/16/halsey-associates-inc-ct-acquires-12370-shares-of-edwards-lifesciences-corp-ew.html.
Edwards Lifesciences Company Profile
Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic heart valves and related delivery systems for the nonsurgical replacement of heart valves.
See Also: What is Net Asset Value (NAV)?
Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corp (NYSE:EW).
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.